Announcements Trials
Browse Landscape

Phase

Phase 1/2 9Phase NA 3Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 1

Interventions

Cisplatin 54Cyclophosphamide 42Fluorouracil 41Oxaliplatin 36Capecitabine 35Docetaxel 34Gemcitabine 32Drug Therapy 32Radiotherapy 31Paclitaxel 25Dexamethasone 23Carboplatin 23Leucovorin 21Etoposide 17Doxorubicin 17Cytarabine 17apatinib 16Methotrexate 16Magnetic Resonance Spectroscopy 14Radiation 13Epirubicin 13Busulfan 13Bevacizumab 13Surgical Procedures, Operative 12Neoadjuvant Therapy 12Letrozole 12Decitabine 12Saline Solution 11Irinotecan 11venetoclax 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Clinical Trials, Phase II as Topic × Clear all
NCT06861777 2025-03-11

Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2/3 Not yet recruiting
474 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡